Marijuana contains more than 460 known different chemicals, including cannabinoids, which exert their actions by binding to the cannabinoid receptor CB1.Reference Ben Amar 1 CB1 receptors are the most highly expressed G protein–coupled receptors in the brainReference Wilson and Nicoll 2 and seem to modulate psychoactive effects, motor control, memory processing, and pain.Reference Wingerchuk 3 The cannabinoid system provides protection against excessive neuronal activity by reducing excitability of hippocampal pyramidal neurons,Reference Wallace 4 and tetrahydrocannabinol (THC) is associated with a serotonin-mediated anticonvulsant effect, according to one experimental study in rats.Reference Ghosh and Bhattacharya 5 Because of all the possible therapeutic applications, marijuana has been used for medical purposes around the world.
Canada is the first country that introduced a regulatory system for medicinal marijuana after a Supreme Court ruling. Legal access has been available since 2001,Reference Santry 6 and the number of patients authorized to use marijuana for medicinal purposes in Canada has grown from approximately 500 people in 2002 to more than 26,000 in 2012. 7 The Canadian Marijuana Medical Access Regulations program allows patients to apply for a license to possess dried marijuana for medicinal purposes if traditional therapies have failed. 8 Under these regulations, patients with symptoms such as nausea, anorexia, cachexia, weight loss, muscle spasms, pain, and seizures associated with multiple sclerosis, severe arthritis, AIDS, cancer, spinal cord injuries or diseases, and epilepsy can possess marijuana legally. 9
The scientific evidence about the anticonvulsant action of marijuana on humans is scanty and controversial. In general, physicians remain unsure whether there are benefits of marijuana that outweigh the risks for patients with epilepsy (PWEs). We aimed to investigate the sociodemographic and clinical characteristics of a group of PWEs with a formal prescription for medicinal marijuana; in addition, we explored the potential clinical effects experienced by patients.
Methods
This study was performed at the Royal University Hospital in Saskatoon, Saskatchewan, Canada. A retrospective review of the 800 clinical charts from the epilepsy outpatient clinic was performed between May and November 2013. Adult PWEs that are authorized to possess dried marijuana for medical purposes were identified and enrolled in the study. The marijuana authorization was given to (1) patients with drug-resistant epilepsy (DRE) who were on polytherapy without response; (2) patients with serious antiepileptic drug (AED) side effects; or (3) patients who asked for authorization and reported beneficial effects of unauthorized marijuana use on epilepsy.
Patients who had consumed marijuana before the medicinal prescription were defined as previous users. Patients who had consumed marijuana at least 48 times the year before the medicinal prescription were defined as previous active users. Patients who had active users as a member of their family or a close friend were defined as patients with family or friend consumption. When a patient reported that marijuana withdrawal produces seizures that only can be controlled with a new dose of marijuana or hospital emergency treatment, they were defined as patients with withdrawal seizure exacerbation. Side effects were considered positive when a patient had to stop marijuana consumption or go to the hospital because of adverse effects. Patients with a history of smoking more than ten cigarettes per day were considered moderate to heavy tobacco smokers. Male patients consuming of more than two drinks per day, or more than 14 drinks per week, and female patients consuming of more than one drink per day, or more than seven drinks per week, were defined as heavy alcohol drinkers. A member of the patient’s family living with medical or social conditions such as severe depression, alcoholism, active illicit drug use, or pathological gambling were defined as dysfunction in the family. When police had arrested a patient, it was defined as having problems with the law.
The estimated median total income before taxes was obtained from the wealth of demographic data for each residential neighborhood in Saskatoon 10 , 11 or the town or village where the patient was living. 12 All these data were gathered from the Canadian Federal Census. The estimated grams in every puff of marijuana were calculated according to Health Canada recommendations. 9 Every joint of marijuana contains 0.5 to 1g of drug and approximately 20% to 70% of THC is delivered in the smoke.
The following information was gathered from charts: epilepsy type, seizures type, and epilepsy syndrome. This information was classified according the recommendations of the International League Against Epilepsy. 13 DRE was determined using the new definitions of the International League Against Epilepsy.Reference Kwan, Arzimanoglou and Berg 14 The history of marijuana consumption was documented in each patient.
Analysis
Descriptive statistics were used according to the type of variable measured. All analysis was performed using SPSS version 20 (SPSS Inc., Chicago, IL, USA).
Results
Demographic Variables
Eighteen patients (12 men and 6 women) were identified holding a prescription of medicinal marijuana from a total population of 800 PWEs in the Saskatchewan epilepsy center (2.2%). The majority of patients were Caucasian (89%) and male (67%) (Table 1). The average median household income of patients before taxes was $52.568±31.421 ($18.401-120.042).
Demographics of the patient population
Clinic Variables
Mean age of patients was 30±7 (19-50) years. The mean age at epilepsy diagnosis was 16±11 (1-43) years. Forty-four percent of patients had more than one seizure per month and 44% had suffered at least one episode of status epilepticus. The mean number of seizures per month when using medicinal marijuana was 3.5±7.4 (0-30). Developmental delay was present in five (28%) patients. Psychiatric comorbidity was common (61%), with depression the most frequent entity. The use of other illicit substances such as stimulants (cocaine or amphetamines), moderate to heavy smoking, or heavy alcohol drinking was also common (61%) (Table 2).
Clinical characteristics of patients
* Stimulants include cocaine and amphetamines.
Eleven (61%) patients had DRE and were also refractory to treatments such as vagal nerve stimulation or ketogenic diet. Seven (39%) patients underwent epilepsy surgery. Three patients had temporal lobectomies, two had callosotomies, and two had tumor resections. Patients had used a large number of AEDs in the past, with a mean of 5±3.5 (1-15). In the last follow-up, patients were using 2.4±1.1 (1-4) AEDs. Fifty percent (5/10) had undergone epilepsy surgery without seizure control, and 20% (2/10) had complex congenital malformations without the possibility of surgical management.
Social Variables
Five (28%) patients had committed criminal offenses. Three (17%) patients were arrested by the police because of frequent postictal violent episodes, one patient was incarcerated because of drug dealing, and one had been arrested on many occasions for unknown reasons. Regarding the families, nine (50%) patients had a family members or close friends who consumed marijuana and eight (44%) patients had a clear history of family dysfunction. Four patients in the study were two pairs of brothers. One was a twin, and both brothers had temporal lobe epilepsy.
Marijuana Consumption
The drug-use pattern was similar among patients (Table 3). Most (89%) had a long history of marijuana use before obtaining a formal prescription, with a mean of 6.6±3.4 (1-15) years. Only two (11%) patients started the medication de novo with the medicinal prescription. These two patients (patients 5 and 11) were complex cases with Lennox-Gastaut syndrome and developmental delay treated with polytherapy, vagal nerve stimulation, and callosotomy without response. In these cases, the family asked for the prescription as a last treatment resource.
Marijuana pattern of use between patients
SC=stimulant consumption; DRE=drug-resistant epilepsy; HAD=heavy alcohol drinker; HC: Health Canada; HTS=heavy tobacco smoker; SE=seizure exacerbation.
Administration route was through cigarettes (smoking) in 15 (83%) patients. Two (11%) patients used marijuana in a “special beverage made at home” by the family (patients 5 and 11) and one (5%) patient used marijuana through vaporization (patient 15). This patient used a vaporizer that heats the plant to release cannabinoids, but remains cool enough to avoid the smoke and toxins associated with combustion. The mean of puff per day when smoking was 4.05±2.87 (0.5-8). In general, the estimated mean consumption was 2.05±1.87 (0.5-8) g per day. Four patients had permission to grow marijuana at home.
Regarding the mode of access, all patients had permission to purchase marijuana from Health Canada, although the sources were variable: four (22%) patients admitted to buying the drug from the government, four (22%) grew and consumed their own marijuana, five (28%) got it from a friend, and the rest (28%) admitted to buying the drug on the street. Only two (11%) patients reported the use of complementary and alternative medicine (CAM) treatments before the marijuana authorization, such as botanical/herbals, vitamins, homeopathic treatment, chiropractic treatment, yoga, special diets, and other “healing therapies.”
In terms of physical and psycho-affective effects, eight (44%) patients never stopped marijuana consumption since receiving their prescriptions, and the other ten (56%) patients have stopped the drug only in special circumstances, such as long flights. All patients that stopped the drug reported exacerbation of withdrawal seizures. None reported status epilepticus as a complication. Only two patients (11%) reported side effects (Table 3). One patient reported an episode of severe motor slowing and drowsiness with drug consumption and another reported complex hallucinations related with paranoid thoughts that required follow-up with a psychiatrist. This patient had a prior diagnosis of psychosis. These patients reported that the benefits of using marijuana outweighed the side effects in every case.
Overall, the mean follow-up since the medical prescription was issued was 26±18 (1-55) months. All patients found marijuana consumption very helpful for seizure control (Table 4). Additionally, they reported relief of poor sleep, poor appetite, and mood difficulties. All patients wanted to continue with the medical prescription and reported excellent daily marijuana compliance.
Personal experiences of patients using medical marijuana
Discussion
There is lack of scientific evidence to endorse marijuana as a medical therapy. There are many concerns from trials such as inconsistency of dosage, number of patients included, and time of treatment.Reference Gloss and Vickrey 15 Additionally there are fears about potential side effects reported in cultured rat hippocampal cells. According to in vitro experiments, THC may induce neuronal death.Reference Chan, Hinds, Impey and Storm 16 In 1976, Feeney published the results of a survey of PWEs in the United States. He reported that 29% of patients younger than age 30 used illegal marijuana after being diagnosed with epilepsy.Reference Feeney 17 Almost 40 years later, the use of marijuana for neurological diseases has increased dramatically.Reference Walsh, Callaway and Belle-Isle 18 However, reports of patients with formal prescriptions are scanty. To the best of our knowledge, this is the first case series study in the literature reporting the potential benefit of medicinal marijuana in adult PWEs.
Demographics
Common sociodemographic features of our patients include young age (19-55 years) and being Caucasian and male. These findings are comparable to the characteristics of people who reported marijuana consumption in the general Canadian populationReference Ogborne and Smart 19 and in patients that use the drug for medical purposes (including epilepsy).Reference Walsh, Callaway and Belle-Isle 18 , Reference Lucas 20 The characteristics of our patients are also similar to the patients reported in other series of PWEs. A recent study reported that males (odds ratio 5.342, 95% confidence interval 1.41-20.15) and young people with epilepsy had a higher chance of being active marijuana users.Reference Hamerle, Ghaeni, Kowski, Weissinger and Holtkamp 21 Using a standardized telephone survey, Gross et al.Reference Gross, Hamm, Ashworth and Quigley 22 reported a high active use of marijuana (drug use within the past year) in PWEs (21%). This study did not show any significant association between marijuana use with age or gender.Reference Gross, Hamm, Ashworth and Quigley 22 In agreement with other studies,Reference Walsh, Callaway and Belle-Isle 18 , Reference Lucas 20 our patients reported using marijuana before the formal prescription was issued and that smoking was the main route of administration.Reference Walsh, Callaway and Belle-Isle 18 , Reference Lucas 20
Effects of Marijuana on Epilepsy
The effects of marijuana on epilepsy are controversial. Some studies report no clear effect of marijuana on seizures and others report a beneficial effect. Interestingly, in our study, the entire population reported a reduction in seizure frequency and severity as well as improved mood and general well-being. Aside from the seizure effects, our patients (89%) reported improved sleep quality and appetite (Table 4). Our results are in agreement with a standardized telephone survey performed by Gross et al.Reference Gross, Hamm, Ashworth and Quigley 22 in Canadian PWEs. In this study, 68% of active marijuana users reported improvement in seizure severity and 54% reported decreased seizure frequency. The rest of patients reported no effect on the seizures, and none reported worsening.Reference Gross, Hamm, Ashworth and Quigley 22 A survey of Canadian consumers of marijuana for different medical purposes showed that in general the drug was perceived to provide effective symptoms relief. More than 70% of patients reported that marijuana was always helpful and 24% described it as often helpful.Reference Walsh, Callaway and Belle-Isle 18 A positive perception was also reported in an online survey addressing the personal experiences of patients in the federal cannabis program. Marijuana was perceived to be an effective treatment for symptoms including pain, nausea, and negative mood.Reference Lucas 20
Not all the studies show positive results. A recent study performed in a German outpatient epilepsy clinicReference Hamerle, Ghaeni, Kowski, Weissinger and Holtkamp 21 showed that most patients who had consumed marijuana did not observe any effect on the disease (84%). Only 15% of active users experienced indirect positive effects on the disease, such as relief from postictal headaches, vomiting, and cramps, and only one patient reported that marijuana helped to reduce the frequency of seizures.Reference Hamerle, Ghaeni, Kowski, Weissinger and Holtkamp 21 In contrast with other studies and ours, seven (11%) patients reported increased seizure frequency associated with marijuana consumption.Reference Hamerle, Ghaeni, Kowski, Weissinger and Holtkamp 21 These negative results are consistent with an American study in which informal interviews were performed in 215 PWEs. In that study, 90% of the patients failed to identify a relationship between marijuana use and seizure frequency or severity. Seven percent believed seizures were less frequent around the time of consumption and 2% believed were more frequent.Reference Gordon and Devinsky 23 However, all of the available studies, including ours, represent samples of patients with self-reported experiences with no formal quantification of seizures or measurements of seizure severity. Also none of the available studies evaluated quality of life before and after the use of marijuana.
Safety
In our study, only two patients reported side effects. According to a recent analysis of four small, randomized clinical trials (48 patients), the dose of 2 to 3 g of Cannabidiol seems to be safe in the short-term (4-24 weeks) in PWEs. Only one clinical trial reported drowsiness. All the studies included in this Cochrane review did not report side effects on patients.Reference Gloss and Vickrey 15 Furthermore, in our case series, 10 (56%) patients reported seizure exacerbation after stopping the drug, a phenomenon previously reported in humans by Hedge et al.Reference Hegde, Santos-Sanchez, Hess, Kabir and Garcia 24 Animal models have also shown rebound effects to THC. Apparently, after exposure to the drug, the withdrawal phase enhances central nervous system excitability, resulting in increased susceptibility to convulsions.Reference Karler, Calder and Turkanis 25
Psychoactive Substances and Psychiatric Comorbidities
Half of the PWEs tried CAM treatments for seizure control.Reference Sirven, Drazkowski, Zimmerman, Bortz, Shulman and Macleish 26 However, neither seizure frequency nor the number of AEDs predicted the use of CAMs.Reference Easterford, Clough, Comish, Lawton and Duncan 27 Marijuana is a drug accepted as a CAM treatment.Reference Sirven, Drazkowski, Zimmerman, Bortz, Shulman and Macleish 26 Individuals who use marijuana are also more likely to use other illicit substances, according to some studies,Reference Gross, Hamm, Ashworth and Quigley 22 , Reference Smith, Farrell, Bunting, Houston and Shevlin 28 and to have a higher tendency to develop psychiatric comorbidityReference Connor, Gullo, Chan, Young, Hall and Feeney 29 as well as being involved with other drug users.Reference Ogborne and Smart 19 The use of other substances (61%) and the presence of psychiatric comorbidity (61%) were common in our patients. Paradoxically, PWEs use marijuana to improve their seizures, although seizure worsening with frequent use of other illicit drugs has been described.Reference Hamerle, Ghaeni, Kowski, Weissinger and Holtkamp 21 The use of illicit substances other than marijuana and the significant psychiatric comorbidity in our patients might explain the high rate of being single, unemployed, and having problems with the law.
Marijuana Access
We found that the majority of patients admitted accessing cannabis through places other than Health Canada (88%). Overall, patients in our study reported lack of satisfaction with the quality of the cannabis supplied by the government. This finding is consistent with a survey performed in 100 federally authorized users. According to that survey, 72% of users reported they were unsatisfied with Canada’s medical cannabis program. When participants were asked about their preferred source for medical cannabis, 99% reported a place different than Health Canada.Reference Lucas 20 Similar findings were reported on an online survey of 628 Canadian consumers of cannabis for therapeutic purposes.Reference Walsh, Callaway and Belle-Isle 18
Limitations
Our study is retrospective and mainly based in self-reported effects of patients, with no formal quantification of seizure frequency and severity. As a result, our results should be interpreted with caution. Another limitation is the lack of a control group. The reduced sample size of this study is the main limitation to performing a direct comparison with another group of PWEs. Our group of patients probably does not reflect the profile of the general population of PWEs, although our study provides critical information in an area where there is controversy and a lack of evidence.
Conclusions
This study shows potential positive effects on seizure activity using medicinal marijuana, but has limitations; therefore, we cannot recommend the use of marijuana for all PWEs. It is possible that some patients could have benefits from medicinal marijuana, such as patients with DRE who are not candidates for epilepsy surgery or in whom surgery did not work. Further prospective studies and randomized clinical trials should examine the potential effect of medicinal marijuana on seizures. The debate will continue until more research is performed. This is one of the few available descriptions of using marijuana as a treatment for epilepsy.
Disclosures
JFT-Z receives grants from the University of Saskatchewan and the Royal University Hospital Foundation in Saskatoon, Saskatchewan, through the Mudjadik Thyssen Mining Professorship in Neurosciences.
